Batoclimab Open-Label Extension Data — AAN 2026
Open-label extension data for batoclimab in gMG at AAN 2026. Watch: durability of MG-ADL improvement, LDL-C trajectory on chronic dosing, IgG rebound off-treatment.
What’s at stake
Batoclimab is a subcutaneous monoclonal antibody developed by Immunovant that blocks the neonatal Fc receptor (FcRn) — a protein in blood vessel walls that recycles immunoglobulin G (IgG) antibodies back into circulation. In autoimmune diseases driven by pathogenic IgG antibodies, blocking FcRn prevents this recycling, accelerating the breakdown of harmful antibodies and reducing disease activity. Batoclimab is in Phase 3 trials for generalized myasthenia gravis; a known class effect of FcRn inhibitors — including the approved competitor VYVGART (efgartigimod) — is LDL cholesterol elevation, which is monitored as a safety endpoint across all batoclimab trials.
IgG-driven autoimmune disorder where antibodies attack neuromuscular junction receptors, causing fluctuating muscle weakness. Affects ~80,000 patients in the US.
Largest neurology meeting in the US (~14,000 attendees). Late-spring; key venue for MG, MS, ALS, and Alzheimer's data.
- AANconferenceAmerican Academy of Neurology Annual Meeting
Largest neurology meeting in the US (~14,000 attendees). Late-spring; key venue for MG, MS, ALS, and Alzheimer's data.
- gMGdiseaseGeneralized Myasthenia Gravis
IgG-driven autoimmune disorder where antibodies attack neuromuscular junction receptors, causing fluctuating muscle weakness. Affects ~80,000 patients in the US.
- MG-ADLendpointMyasthenia Gravis Activities of Daily Living
An 8-item, patient-reported scale (0-24) tracking daily-life impact of myasthenia gravis. Lower scores = less disability. A 2-point reduction is considered clinically meaningful.
- LDL-CendpointLow-density lipoprotein cholesterol
"Bad" cholesterol. FcRn inhibitors are known to elevate LDL by 20-40%, which matters for chronic dosing in patients with cardiovascular risk.
- IgGtargetImmunoglobulin G
The most common antibody class. Pathogenic IgG drives autoimmune disease in MG, ITP, TED. FcRn inhibitors lower total IgG by ~60-75% to reduce the autoimmune attack.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| DUPIXENTdupilumab | REGN | mAb | IL-4Rα blocker | READOUT · Jan 27 | |
| NTLA-2002 | NTLA | gene therapy | in vivo CRISPR knockout of KLKB1 | ENROLLMENT · Sep 26 | |
| ORLADEYOberotralstat | BCRX | small molecule | plasma kallikrein inhibitor | CMC · Jun 26 |
Disclosure trail
- Apr 15, 2026·15d agopinned · highest confidenceHIGH conf8-KEXACTtop claimAPR 302026
“Open-label extension data for batoclimab in generalized myasthenia gravis will be presented at the American Academy of Neurology Annual Meeting on April 30, 2026.”
conf 94%via llm